Pravachol, Pravafenix (pravastatin) is a small molecule pharmaceutical. Pravastatin was first approved as Pravachol on 1991-10-31. It is used to treat coronary artery disease, hypercholesterolemia, hyperlipoproteinemias, and hypertriglyceridemia in the USA. It has been approved in Europe to treat dyslipidemias. The pharmaceutical is active against 3-hydroxy-3-methylglutaryl-Coenzyme A reductase. In addition, it is known to target solute carrier organic anion transporter family member 1B1.
|Indication||coronary artery disease, dyslipidemias, hypercholesterolemia, hyperlipoproteinemias, hypertriglyceridemia|
|Drug Class||Enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)|